Mease PJ, Chohan S, Fructuoso FJG, et al. - In this randomised, double-blind, placebo-controlled, phase IIb study, other than dactylitis and enthesitis, tildrakizumab [a high-affinity anti-IL-23p19 monoclonal antibody] treatment significantly reduced psoriatic arthritis (PsA) joint and skin symptoms. Through W52, the treatment was generally well tolerated.

• A total of 391 of the 500 patients who were screened were randomly assigned and treated.

• At W24, 71.4%–79.5% of tildrakizumab-treated patients achieved ACR20 (≥ 20% improvement by American College of Rheumatology criteria), compared with 50.6% of placebo-treated patients. Patients who received tildrakizumab vs placebo had higher rates of ACR50, Disease Activity Score in 28 joints with C reactive protein < 3.2, minimal disease activity, and 75%/90%/100% improvement from baseline Psoriasis Area and Severity Index responses at W24 and through W52.

• Dactylitis and enthesitis did not improve, while the findings for other outcomes were inconsistent.

• Patients who were shifted to tildrakizumab 200 mg at W24 had responses that were consistent with baseline therapy.

• Through W52, TEAEs and significant TEAEs occurred in 64.5% and 3.3% of all participants, respectively, and were equivalent across treatment groups.